Report from the annual general meeting in DexTech Medical AB on 17 October 2019
Today, October 17, 2019, the Annual General Meeting of DexTech Medical AB was held. Below is a summary of the decisions that were made. All decisions were made with the required majority.
Decision on the adoption of the income statement and balance sheet
The Meeting resolved to adopt the presented income statement and balance sheet.
Decision on allocations regarding the company's earnings in accordance with the adopted balance sheet
The AGM decided to dispose of the company's earnings, and that no dividend is paid for the financial year 2018/2019.
Resolution on discharge for the members of the Board of Directors and the Managing Director
The annual general meeting resolved to discharge the board members and the managing director from liability.
Determination of the number of board members and deputy directors
The AGM resolved that the number of board members should be unchanged five members and that no deputies be elected.
Determination of fees for the Board of Directors and the auditors
The AGM resolved that board fees should not be paid and that fees to the auditor be paid in accordance with approved invoice.
Election of Board of Directors and auditors
The Meeting resolved to re-elect Svante Wadman, Anders Holmberg, Sten Nilsson, Per-Olof Asplund and Rolf Eriksson. At the subsequent statutory Board meeting, Svante Wadman was re-elected as Chairman of the Board. KPMG AB was re-elected, with Petra Lindström as responsible auditor, as auditor for the period until the end of the next AGM.
For additional information:
Gösta Lundgren - CFO & Investor Relations
DexTech Medical AB
Telephone: +46 (0) 707104788
E-mail: gosta.lundgren@dextechmedical.com
The information was submitted for publication on October 17, 2019, through the contact of the above contact person.
DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with skeletal metastases. A successful Phase II clinical trial has been conducted with OsteoDex where the result shows high tolerability with mild side effects as well as treatment effect on patients who fail on existing drugs. DexTech's goal is to license the respective drug candidate by the latest phase II study. DexTech Medical AB is listed on the Spotlight Stock Market.